Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
about
Nonsteroidal anti-inflammatory drugs for assisted reproductive technologyNitrate/Nitrite as Critical Mediators to Limit Oxidative Injury and InflammationTherapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographicsA nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug useUpper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugsCOX-2 chronologyThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaCurrent approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondProton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugsAn economic model of long-term use of celecoxib in patients with osteoarthritisIncreased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugsEvaluation and management of dyspepsia.COX-2 inhibition: what we learned--a controversial update on safety data.Accounting for the increase in NSAID expenditure: substitution or leakage?A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritisNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors.Which drugs cause preventable admissions to hospital? A systematic review.Chronic NSAIDs Use Increases the Risk of a Second Hip Fracture in Patients After Hip Fracture Surgery: Evidence From a STROBE-Compliant Population-Based Study.New formulation of old aspirin for better deliveryDesign of indomethacin-loaded nanoparticles: effect of polymer matrix and surfactant.Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological studyLeaves of Raphanus sativus L. Shows Anti-Inflammatory Activity in LPS-Stimulated Macrophages via Suppression of COX-2 and iNOS ExpressionImpact of safety-related regulatory action on clinical practice: a systematic review.Algorithm for anticoagulation management in geriatric hip fracture patients--Surgeons save Blood.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules.Adverse drug reactions experience in a teaching hospital in Jordan.Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.New dogmas or old?Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cellsRole of Rosiglitazone as a Gastroprotective Agent Against Indomethacin-Induced Gastric Mucosal Injury in Rats.Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.Cost-Utility Analysis of High Molecular Weight Hyaluronic Acid for Knee Osteoarthritis in Everyday Clinical Care in Patients at a Working Age: An Economic Evaluation of a Randomized Clinical Trial.Use of a cyclo-oxygenase 2 inhibitor for prophylaxis of cystoid macular oedema following cataract surgery: a randomized placebo-controlled trial.Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism.Role of Rosiglitazone as a Gastroprotective Agent Against Indomethacin-Induced Gastric Mucosal Injury in Rats.Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitorsFucofuroeckol-A fromEisenia bicyclisInhibits Inflammation in Lipopolysaccharide-Induced Mouse Macrophages via Downregulation of the MAPK/NF-κB Signaling Pathway
P2860
Q24242315-BB032CC1-0319-486F-8CAB-A95043156C3BQ27021987-6FE6389D-66FF-4711-A794-67298F4569D4Q28169144-213F3AB9-73B2-491C-A7C5-6A9F9370459CQ28186337-9007A89B-1641-460F-92DD-4D27CC179022Q28186823-758D976D-4D2F-4DCD-B28C-99A91F191A47Q28192719-63A4DD90-D19B-4C21-BCEE-C98FB2C807DEQ28194351-814F420A-3954-4D2C-8FC1-9BB97E57244AQ28210656-487D27CF-D66A-40AE-AB91-9E84D0D3FCF1Q28210875-C91D7AB4-C0CF-4D5D-8E78-691182E9A5F3Q28218005-B644CFAD-D9A0-4409-B981-96179638DB8BQ28218432-B75297E8-D97E-4353-A890-51E48022CCACQ30433839-CE6ADE01-6302-4C88-A106-971C5E660FAFQ30724476-510C4AAB-B9CC-4A9B-821C-9D304286507FQ34768089-5AF30878-353A-40C9-88AF-1DD98E18C3AEQ35555299-2FBAEF61-D783-4BBD-9878-572225082105Q35873871-DE6C80A0-2F8F-4817-973F-7C06E3E31B17Q35976831-D3FD7097-7621-4333-94DB-42A59138F302Q36024335-FB93C93E-C1E2-4847-AC87-3B4C6AC04C76Q36255940-E2E2306B-E167-479C-A698-1AEA619E8163Q36373219-2688DCBC-3337-4049-B74A-34E39E89DE09Q37209614-5713AA2C-134A-4D51-989B-9D9956F4B2B8Q37471109-95B2D7B4-990A-41DA-8562-5B22FCC4F16EQ37740057-502E0B5C-C6FC-4D96-BD5D-0D6420007AACQ38000336-25F5E9FE-A45E-4B60-B955-CF0CBE1575FFQ38195191-D8B73516-9378-4211-8386-1F6D5E3B62C5Q38760434-85456965-E5C4-4A5B-800A-7F639384AE6DQ39251183-82C0FDE7-1ADD-4463-9835-D39BBC22F25CQ40142716-917E4105-4C8F-4AAD-A82E-8E715E84D3D7Q40156599-3443300E-BC37-4546-AB46-DE70B9E94840Q41903025-0DEBFAE0-5C98-4B98-A902-71EDF3590C22Q42199704-97A487D4-F935-44D2-BB76-306AAE88B150Q46684086-C07BD251-2D22-4609-905A-ED6921CF869CQ46957598-CF1CDAFA-44CB-44A1-A21D-90528EA4A805Q47227397-49F21C40-6640-4FDC-9A74-06137E18760DQ48691658-A667EBDB-0D6E-4FC8-8BBE-AB05866F3271Q52627350-D31B2399-14A3-4FA9-A163-6086F903EBE8Q54850582-0AA5B1EB-C929-4817-A5B5-22E7B417A4F1Q57300663-7D91E57C-CDA6-4426-B8E1-A38D38ECFFB8Q59125643-14806412-060C-4834-9FC4-BF3C4CFF2B3C
P2860
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@ast
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@en
type
label
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@ast
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@en
prefLabel
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@ast
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@en
P2860
P356
P1433
P1476
Non-steroidal anti-inflammator ...... rs and proton pump inhibitors.
@en
P2093
C J Hawkey
M J S Langman
P2860
P304
P356
10.1136/GUT.52.4.600
P407
P577
2003-04-01T00:00:00Z